In Brief: Transmissible spongiform encephalopathies
This article was originally published in The Tan Sheet
Executive Summary
Transmissible spongiform encephalopathies: FDA advisory committee on transmissible spongiform encephalopathies scheduled to meet April 15-16. Discussion the first day will focus on the safety of tallow and tallow derivatives used in pharmaceuticals, cosmetics and other FDA-regulated products as well as U.S. and global issues on nonedible tallow. On April 16, the committee will discuss gelatin and dura mater products. The meeting will be held at the Holiday Inn, Bethesda, Md..
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning